KR102686313B1 - 델타 간염 바이러스 감염의 치료 - Google Patents

델타 간염 바이러스 감염의 치료 Download PDF

Info

Publication number
KR102686313B1
KR102686313B1 KR1020167033817A KR20167033817A KR102686313B1 KR 102686313 B1 KR102686313 B1 KR 102686313B1 KR 1020167033817 A KR1020167033817 A KR 1020167033817A KR 20167033817 A KR20167033817 A KR 20167033817A KR 102686313 B1 KR102686313 B1 KR 102686313B1
Authority
KR
South Korea
Prior art keywords
lonafarnib
ritonavir
administered
hdv
bid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167033817A
Other languages
English (en)
Korean (ko)
Other versions
KR20170005827A (ko
Inventor
데이비드 코리
인그리드 충
제프리 에스. 글렌
Original Assignee
아이거 바이오파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이거 바이오파마슈티컬스 인코포레이티드 filed Critical 아이거 바이오파마슈티컬스 인코포레이티드
Priority to KR1020247023478A priority Critical patent/KR20240112990A/ko
Priority to KR1020237014993A priority patent/KR20230062688A/ko
Publication of KR20170005827A publication Critical patent/KR20170005827A/ko
Application granted granted Critical
Publication of KR102686313B1 publication Critical patent/KR102686313B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167033817A 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료 Active KR102686313B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020247023478A KR20240112990A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료
KR1020237014993A KR20230062688A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461987315P 2014-05-01 2014-05-01
US61/987,315 2014-05-01
US201462044766P 2014-09-02 2014-09-02
US62/044,766 2014-09-02
US201462073413P 2014-10-31 2014-10-31
US62/073,413 2014-10-31
US201562151349P 2015-04-22 2015-04-22
US62/151,349 2015-04-22
PCT/US2015/028933 WO2015168648A1 (en) 2014-05-01 2015-05-01 Treatment of hepatitis delta virus infection

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020237014993A Division KR20230062688A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료
KR1020247023478A Division KR20240112990A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료

Publications (2)

Publication Number Publication Date
KR20170005827A KR20170005827A (ko) 2017-01-16
KR102686313B1 true KR102686313B1 (ko) 2024-07-17

Family

ID=54359409

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167033817A Active KR102686313B1 (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료
KR1020247023478A Pending KR20240112990A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료
KR1020237014993A Ceased KR20230062688A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247023478A Pending KR20240112990A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료
KR1020237014993A Ceased KR20230062688A (ko) 2014-05-01 2015-05-01 델타 간염 바이러스 감염의 치료

Country Status (13)

Country Link
EP (2) EP3137078B1 (enExample)
JP (1) JP6490800B2 (enExample)
KR (3) KR102686313B1 (enExample)
CN (2) CN111265525A (enExample)
CY (1) CY1121924T1 (enExample)
DK (1) DK3137078T3 (enExample)
ES (1) ES2728405T3 (enExample)
HU (1) HUE044606T2 (enExample)
LT (1) LT3137078T (enExample)
PL (1) PL3137078T3 (enExample)
PT (1) PT3137078T (enExample)
SI (1) SI3137078T1 (enExample)
WO (1) WO2015168648A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
EP3858352A1 (en) * 2015-11-04 2021-08-04 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR20180110127A (ko) * 2016-02-19 2018-10-08 아이거 바이오파마슈티컬스 인코포레이티드 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료
JP2020510480A (ja) * 2017-03-01 2020-04-09 ナショナル ユニバーシティ オブ シンガポール マイクロニードルデバイス
WO2024223797A1 (en) * 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
CA2424222A1 (en) * 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1365763B1 (en) * 2001-02-15 2008-11-26 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
EP1998759A2 (en) * 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008137692A1 (en) * 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
US20090087483A1 (en) 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
US20110313009A1 (en) 2008-07-17 2011-12-22 Horizon Pharma Usa, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP2421527B1 (en) * 2009-04-25 2018-06-13 F.Hoffmann-La Roche Ag Methods for improving pharmacokinetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088126A2 (en) * 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors

Also Published As

Publication number Publication date
JP6490800B2 (ja) 2019-03-27
HUE044606T2 (hu) 2019-11-28
CN111265525A (zh) 2020-06-12
CN106535895A (zh) 2017-03-22
KR20170005827A (ko) 2017-01-16
EP3620163A1 (en) 2020-03-11
ES2728405T3 (es) 2019-10-24
SI3137078T1 (sl) 2019-08-30
KR20230062688A (ko) 2023-05-09
PL3137078T3 (pl) 2019-08-30
KR20240112990A (ko) 2024-07-19
LT3137078T (lt) 2019-06-25
PT3137078T (pt) 2019-06-11
EP3137078B1 (en) 2019-03-20
JP2017514911A (ja) 2017-06-08
EP3137078A1 (en) 2017-03-08
WO2015168648A1 (en) 2015-11-05
CN106535895B (zh) 2020-02-28
EP3137078A4 (en) 2017-11-15
CY1121924T1 (el) 2020-10-14
DK3137078T3 (da) 2019-06-11

Similar Documents

Publication Publication Date Title
KR102686313B1 (ko) 델타 간염 바이러스 감염의 치료
US10828283B2 (en) Treatment of hepatitis delta virus infection
JP2025020188A (ja) デルタ型肝炎ウイルス感染の処置
US12290509B2 (en) Treatment of hepatitis delta virus infection
US20220023287A1 (en) Treatment of hepatitis delta virus infection
US10835496B2 (en) Pharmaceutical compositions comprising lonafarnib and ritonavir
US8912141B2 (en) Treatment of hepatitis C virus
JP2017536403A5 (enExample)
US20250387377A1 (en) Treatment of hepatitis delta virus infection
US20090035273A1 (en) Combination treatment method with interferon-tau
WO2013137869A1 (en) Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211206

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220810

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211206

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220810

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220404

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200128

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221207

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20221110

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220810

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220404

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211206

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200128

X601 Decision of rejection after re-examination
A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230502

PJ0201 Trial against decision of rejection

Patent event date: 20230502

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20221207

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220810

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101000960

Request date: 20230502

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101000960; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230502

Effective date: 20240321

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20240321

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230502

Decision date: 20240321

Appeal identifier: 2023101000960

PS0901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

Patent event date: 20240415

Patent event code: PS07012S01D

Comment text: Decision to Grant Registration

Patent event date: 20240321

Patent event code: PS07011S01I

Comment text: Notice of Trial Decision (Remand of Revocation)

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240715

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240715

End annual number: 3

Start annual number: 1

PG1601 Publication of registration